Performance of Two Intraocular Lenses With Extended Depth of Vision

Sponsor
Vienna Institute for Research in Ocular Surgery (Other)
Overall Status
Recruiting
CT.gov ID
NCT05194150
Collaborator
(none)
48
1
2
24
2

Study Details

Study Description

Brief Summary

Comparison of the capsular bag performance of two extended depth of vision (EDOF) intraocular lenses (IOLs), the Rayone EMV and the Alcon Acrysof IQ Vivity, in a mini-monovision setting

Condition or Disease Intervention/Treatment Phase
  • Device: non-diffractive monofocal IOL
  • Device: standard EDOF IOL
N/A

Detailed Description

Spectacle independence is a rising aim in modern cataract surgery. Although bilateral monofocal IOL implantation, aiming for emmetropia leads to high levels of patient satisfaction for distance vision, spectacle dependence for reading and intermediate vision tasks is the usual result.

The option commonly used to achieve spectacle independence in all distances are multifocal intraocular lenses. One concept of multifocality is the trifocal lens. This lens provides good vision in three focal distances: far, intermediate, and near. However, one potential disadvantage of trifocal IOLs is slightly poorer near vision with need for reading gasses for prolonged fine near work and loss of contrast sensitivity in the intermediate distance.

A better intermediate performance concerning contrast vision compared to trifocal IOLs can be reached using enhanced depth of focus (EDOF) lenses. These IOLs have an extended far focus area, which reaches to the intermediate distance, providing high-quality vision over a continuous range of focus, rather than distinct foci with blur in between. In the last years several technologies for EDOF IOLs appeared on the market. The disadvantage compared to monofocal lenses in all of these technologies is the potentially worse contrast sensitivity as well as dysphotopsia.

A new monofocal non-diffractive lens with an extended depth of vision (Rayone EMV) promises an increased range of functional vision and less dysphotopsias. Especially in a monovision setting, where the dominant eye is set for emmetropia and the other eye for low myopia is believe dto be a promising concept for spectacle independence.

Hence, the aim of this study is to compare a new monofocal IOL wit a non-diffractive extended depth of vision (Rayone EMV) with an already established non-diffractive EDOF IOL (Alcon Acrysof IQ Vivity) in a mini-monovision setting.

96 eyes of 48 patients will be included into this study. After randomization, each patient will either receive the Rayone EMV or the Alcon Acrysof IQ Vivity in both eyes. Follow-up visits will be 2 weeks and 3 months after surgery. During these visits a slitlamp examination, measurement of the intraocular pressure, visual acuity assessment, pupil size measurement, determination of the defocus curve, contrast sensitivity measurements, reading speed detection, and a flaremeter measurement will be performed.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
48 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Treatment
Official Title:
Performance of Two Non-diffractive Intraocular Lenses With Extended Depth of Vision Set for Mini-monovision
Actual Study Start Date :
Jan 3, 2022
Anticipated Primary Completion Date :
Jan 3, 2023
Anticipated Study Completion Date :
Jan 3, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Rayone EMV

Patient will receive the non-diffractive monofocal IOL during cataract surgery

Device: non-diffractive monofocal IOL
Rayone EMV

Experimental: Acrysof IQ Vivity

Patient will receive the standard EDOF IOL during cataract surgery

Device: standard EDOF IOL
Acrysof IQ Vivity

Outcome Measures

Primary Outcome Measures

  1. Visual acuity at intermediate distance [24 months]

    The visual acuity at the intermediate distance will be measured using ETDRS charts at a distance of 80 centimetres and compared between the two different IOLs

Secondary Outcome Measures

  1. Visual acuity at far distance [24 months]

    The visual acuity at the far distance will be measured using ETDRS charts at a distance of 4 metres and compared between the two different IOLs

  2. Visual acuity at near distance [24 months]

    The visual acuity at the near distance will be measured using ETDRS charts at a distance of 40 centimetres and compared between the two different IOLs

  3. Visual acuity in the defocus curve [24 months]

    The visual acuity in the defocus curve will be measured using ETDRS charts at 4 metres with the patient wearing glasses in the power range of -3.5 to +1.0 diopters (presented in 0.5 dioptre steps) and will be compared between the two IOLs

  4. Halometry [24 months]

    The size of the halos depicted in degrees will be assessed using the aston halometer and will be compared between the two IOLs

  5. Contrast sensitivity [24 months]

    Contast sensitvity will be measured using the Optec Vision tester and will be compared between the two IOLs

  6. Reading speed [24 months]

    Reading speed will be assessed with teh Salzburg Reading Desk and will be compared between the two different IOLs

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years to 105 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • age-related bilateral cataract

  • age 21 or older

  • visual acuity > 0.05

  • axial length: 22.0 - 26.0 mm

  • normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant

  • written informed consent prior to surgery

Exclusion Criteria:
  • active ocular disease (e.g. chronic severe uveitis, proliferative diabetic retinopathy, chronic glaucoma not responsive to medication)

  • relevant othe rophthalmic diseases such as pseudoexfoliation syndrome (PEX), intraoperative floppy iris syndrome (IFIS)

  • corneal decompensation or corneal endothelial cell insufficiency

  • previous ocular surgery or trauma

  • persons who are pregnant or nursing (pregnancy test will be taken in women of reproductive age)

  • corneal astigmatism > 1 dpt.

  • retinopathies

Contacts and Locations

Locations

Site City State Country Postal Code
1 Vienna Institute for Research in Ocular Surgery (VIROS), Hanusch Hospital Vienna Vienna Austria 1140

Sponsors and Collaborators

  • Vienna Institute for Research in Ocular Surgery

Investigators

  • Principal Investigator: Oliver Findl, MD, Vienna Institute for Research in Ocular Surgery (VIROS), Hanusch Hospital Vienna

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Prim. Prof. Dr. Oliver Findl, MBA, Principal Investigator, Vienna Institute for Research in Ocular Surgery
ClinicalTrials.gov Identifier:
NCT05194150
Other Study ID Numbers:
  • Rayner Performance
First Posted:
Jan 18, 2022
Last Update Posted:
Jan 18, 2022
Last Verified:
Jan 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Prim. Prof. Dr. Oliver Findl, MBA, Principal Investigator, Vienna Institute for Research in Ocular Surgery
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 18, 2022